Penerangan produk
Indikasi
1.1 INLYTA avelumab RCC INLYTA pembrolizumab RCC 1.2 INLYTA RCC
Mekanisme Tindakan
VEGFR -1 VEGFR-2 VEGFR-3 , VEGF , , VEGFR-2
Farmakologi
12.1 Mekanisme Tindakan , , VEGFR -1 VEGFR-2 VEGFR-3 , VEGF , , VEGFR-2
Dos dan Cara Penggunaan
2.1 (RCC) INLYTA Avelumab INLYTA 5 mg, 12 , , Avelumab 800 mg, 2 60 , INLYTA Avelumab , 5 mg , INLYTA Avelumab , INLYTA Pembrolizumab INLYTA 5 mg, 12 , , Pembrolizumab 200 mg, 3 , 400 mg, 6
Langkah Berjaga-jaga
5.1 INLYTA RCC , INLYTA 359 145 40% , 355 103 29% INLYTA 359 56 16% 3/4 , 355 39 11% 3/4 2/359 INLYTA ≥150 mmHg >100 mmHg , INLYTA 4 1/359 INLYTA
Interaksi Ubat
7.1 CYP3A4/5 , CYP3A4/5 INLYTA CYP3A4/5 , CYP3A4/5
Kesan Sampingan
[ Langkah Berjaga-jaga(5)] • [ Langkah Berjaga-jaga(5.1)] • [ Langkah Berjaga-jaga(5.2)] • [ Langkah Berjaga-jaga(5.3)] • [ Langkah Berjaga-jaga(5.4)] • [ Langkah Berjaga-jaga(5.5)] • [ Langkah Berjaga-jaga(5.6)] • [ Langkah Berjaga-jaga(5.7)] • [ Langkah Berjaga-jaga(5.9)] • [ Langkah Berjaga-jaga(5.10)] [ Langkah Berjaga-jaga]
Penyimpanan
INLYTA • 1 , “Pfizer”, “1 XNB” 180 NDC 0069-0145-01 • 5 , “Pfizer”, “5 XNB” 60 NDC 0069-0151-11 • 20°C 25°C 68°F 77°F
